Treatment of Alzheimer disease with tacrine: A cost-analysis model

Alzheimer Disease and Associated Disorders

Volumn 11, Issue 4, 1997, Pages 191-200

  Wimo, Anders ^a,b,f   Karlsson, Göran ^c   Nordberg, Agneta ^d   Winblad, Bengt ^d,e  

^a Devmt Unit of Primary Health Care   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e STOCKHOLM GERONTOLOGY RESEARCH CENTER   (Sweden)

^f Box 16 ^*  (Sweden)

Author keywords

Cost analysis; Cost minimization analysis; Costs; Dementia; Sweden; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; SURVIVAL; SWEDEN;

ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, THEORETICAL; PSYCHOLOGICAL TESTS; SENSITIVITY AND SPECIFICITY; SWEDEN; TACRINE;

EID: 0031460557     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Andersson M. Institutionalization of the elderly and characteristics of nursing home patients. Compr Gerontol 1989;3:1-7.
2. Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Prognostic factors in very-old demented: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc (in press).
3. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991;337:989-92.
4. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1-4.
5. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental' State: a practical method for grading the cognitive state of patients for the clinician. Psychiatr Res 1975;12:189-98.
6. Fratiglioni L, Forsell Y, Agüero-Torres H, Winblad B. Severity of dementia and institutionalization in the elderly: prevalence data from an urban area in Sweden. Neuroepidemiology 1994;13:79-88.
7. Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relation with age, sex and education. Neurology 1991;41:1886-92.
8. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996:309.
9. Gray A, Fenn P. Alzheimer's disease: the burden of illness in England. Health Trends 1993;25:31-7.
10. Harvey RJ, Eagger SA. The clinical efficacy of tacrine. Rev Contemp Pharmacother 1995;6:335-48.
11. Holmberg H, Carlsson P. Vilka effekter her en ändrad åldersstruktur på kostnader för stöd till äldre i hemmet och särskilt boende aring;r 2000? [What are the effects of a changed age structure on costs and support to the elderly at home and in sheltered living in the year 2000? Stockholm, Sweden: Socialstyrelsen (The National Board of Health and Welfare) 1993:12. [In Swedish with an English summary.]
12. Ineichen B. Senile dementia: policy and services. London: Chapman and Hall, 1989.
13. Johansson L. Caring for the next of kin [Dissertation]. Uppsala, Sweden: Department of Social Medicine, University of Uppsala, Sweden, 1991.
14. Kavanagh S, Schneider J, Knapp MRJ, Beecham J, Netten A. Elderly people with cognitive impairment: costing possible changes in the balance of care. Health Soc Care Commun 1995;2:69-80.
15. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
16. Knopman D, Schneider L, Davis K, et al. Long-term tacrine treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
17. Knopman D. Tacrine for Alzheimer's disease: costs and benefits. Pharmacoeconomics 1995;7:275-9.
18. Lubeck DP, Mazonson PD, Bowe T. The potential impact of tacrine on expenditures for Alzheimer's disease. Med Interface 1994;7:130-8.
19. Max W. The cost of Alzheimer's disease: will drug input ease the burden? Pharmacoeconomics 1996;9:5-10.
20. Nordberg A. Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol Scand 1992;139(Suppl):54-8.
21. OECD. Health data/ECO-Sante-OECD. Paris, 1995. [Data file.]
22. Østbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994;151:1457-64.
23. Pendlebury WW, Solomon PR. The tolerability and safety profile of tacrine. Rev Contemp Pharmacother 1995;6:349-57.
24. Reisberg B, Ferris SH, Kluger A, et al. Symptomatic changes in CNS aging and dementia of the Alzheimer type: cross-sectional, temporal and remediable concomitants. In: Bergener M, Reisberg B, eds. Diagnosis and treatment of senile dementia. Berlin/Heidelberg: Springer-Verlag, 1989:193-223.
25. Rice DP, Fox P-J, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993;12(Summer):164-76.
26. Salmon DP, Thai LJ, Butters N, et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-30.
27. Skoog I. Mental disorders in the elderly: a population study in 85-year-olds [Thesis]. Göteborg, Sweden: Department of Psychiatry, University of Göteborg, 1993.
28. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
29. Thorslund M. The de-institutionalization of care of the elderly: some notes about implentation and outcome of a Swedish case-study. Health Policy 1988;10:44-56.
30. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
31. Wimo A, Eriksson T, Mattsson B, Krakau I, Nelvig A, Karlsson G. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995a;11:49-65.
32. Wimo A, Karlsson G, Sandman PO, Winblad B. Vården av dementa -en tickande kostnadsbomb? [Care of demented people - a time bomb of costs?]. Nordisk Medicin 1995b;110:123-6. [In Swedish, English summary.]
33. Wimo A, Karlsson G, Sandman PO, Corder L, Winblad B. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997;12:857-61.
34. Wimo A, Mattsson B, Gustafsson L. Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders. Scand J Prim Health Care 1992;10:185-91.
35. Winblad B, Ljungren G, Karlsson G, Wimo A. What are the costs for the society and for individuals regarding diagnostic procedures and care of patients with dementia. Acta Neurol Scand 1996;168(Suppl):101-4.